Reasons Behind Thursday's Increase in Reddit Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2025
0mins
Should l Buy JEF?
Source: Fool
Reddit's Stock Performance: Reddit's share price rose nearly 1%, reaching an all-time high, following a positive report from Jefferies, which reiterated a buy recommendation and increased the price target to $320 per share.
Revenue Growth Potential: Analysts at Jefferies are optimistic about Reddit's revenue growth, projecting a 35% increase over current estimates for 2027, supported by a strong second quarter where revenue grew 78% year-over-year to $500 million, resulting in a net profit of $89 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JEF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JEF
Wall Street analysts forecast JEF stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.570
Low
55.00
Averages
72.79
High
97.00
Current: 47.570
Low
55.00
Averages
72.79
High
97.00
About JEF
Jefferies Financial Group Inc. is a global investment banking and capital markets company. The Company's segments include Investment Banking and Capital Markets and Asset Management. The Investment Banking and Capital Markets segment includes its capital markets activities and its investment banking business, which provides underwriting and financial advisory services to its clients. It operates in the Americas; Europe and the Middle East; and Asia-Pacific. The Investment Banking and Capital Markets segment provides the sales, trading, origination and advisory effort for various fixed income, equity and advisory products and services. The Asset Management segment provides alternative investment management services to investors globally and generates investment income from capital invested in and managed by it or its affiliated asset managers and includes certain remaining businesses and assets of its legacy merchant banking portfolio.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Buffett Retires, Abel Takes Over as CEO of Berkshire Hathaway
- Leadership Transition: Warren Buffett retired on December 31, 2025, with Greg Abel stepping in to manage Berkshire Hathaway's $320 billion investment portfolio, marking a significant new era for the company.
- Investment Concentration: Abel's portfolio is heavily weighted, with 10 core holdings accounting for nearly 79% of assets, including Apple at $60 billion, highlighting the company's focus on high-quality assets and long-term growth potential.
- Sustainable Competitive Advantages: Among the 20 billion-dollar investments Abel oversees, many companies like Visa and Sirius XM operate as legal monopolies, ensuring stable revenue streams and risk resilience, reflecting Berkshire's investment strategy.
- Smaller Holdings Adjustment: Abel also manages 18 relatively smaller investments, with significant reductions like the 77% cut in Amazon's stake, indicating a focus on optimizing the portfolio and potentially paving the way for future trading opportunities.
See More
Warren Buffett Retires, Greg Abel Takes Over as CEO of Berkshire Hathaway
- Leadership Transition: Warren Buffett retired as CEO on December 31, 2025, with Greg Abel taking over the management of a $320 billion investment portfolio, marking a new era for Berkshire Hathaway, although Buffett remains as chairman of the board.
- Investment Philosophy Continuity: Abel shares a similar investment philosophy with Buffett, emphasizing value investing and sustainable competitive advantages, particularly by allocating a significant portion of the company's capital to their best ideas.
- Core Holdings Concentration: The ten core positions account for nearly 79% of Berkshire's invested assets, all of which pay dividends and engage in share repurchases, demonstrating strong capital return capabilities, with Abel's management style reflected in these choices.
- Smaller Investment Dynamics: Abel oversees 18 smaller holdings ranging from $5 million to approximately $692 million, many of which are being reduced or removed from the portfolio, indicating a dynamic adjustment strategy in response to market conditions.
See More
Jefferies Financial Group Shares Rise 3.3% Amid Middle East Ceasefire
- Stock Price Surge: Jefferies Financial Group's shares rose 3.3% to $48.10 following the ceasefire in the Middle East, reflecting market optimism about the rebound in global equity prices and asset valuations, which directly boosts the company's assets under management and associated fee revenue.
- Return to Risk Assets: The de-escalation in the Middle East encourages retail and institutional investors to rotate back into riskier assets, which is expected to drive revenue growth in investment banking and brokerage divisions, particularly in corporate M&A and advisory activities, creating a potential 'deal-making spring'.
- Market Volatility: Jefferies' stock has experienced 16 moves greater than 5% over the past year; while today's increase is seen as significant, it indicates that the market's fundamental perception of the business remains unchanged, reflecting cautious optimism among investors regarding future prospects.
- Long-Term Investment Returns: Despite a 23.8% decline in Jefferies' stock price year-to-date, investors who purchased $1,000 worth of shares five years ago would now see their investment grow to $1,479, indicating the company's long-term attractiveness, especially in a stable economic environment.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
Jefferies Financial Group Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Jefferies Financial Group and its executives engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Bankruptcy Fallout: Jefferies faces approximately $715 million in debt risk due to its ties with the bankrupt auto parts manufacturer First Brands, resulting in a 7.88% drop in its stock price on October 8, 2025.
- Regulatory Scrutiny: The U.S. Securities and Exchange Commission is investigating whether Jefferies provided sufficient information to investors in its Point Bonita fund, raising further concerns about its transparency in the market.
- Increased Litigation Risk: Western Alliance Bancorp is suing Jefferies, alleging that it failed to fulfill commitments on a large commercial loan, causing its stock price to plummet by 13.53% on March 6, 2026.
See More
Buffett Retires, Abel Takes Over as CEO of Berkshire Hathaway
- Leadership Transition: Warren Buffett retired on December 31, 2025, with Greg Abel stepping in to manage Berkshire Hathaway's $320 billion investment portfolio, marking a significant new era for the company.
- Investment Concentration: Abel's portfolio is heavily weighted, with 10 core holdings accounting for nearly 79% of assets, including Apple at $60 billion, highlighting the company's focus on high-quality assets and long-term growth potential.
- Sustainable Competitive Advantages: Among the 20 billion-dollar investments Abel oversees, many companies like Visa and Sirius XM operate as legal monopolies, ensuring stable revenue streams and risk resilience, reflecting Berkshire's investment strategy.
- Smaller Holdings Adjustment: Abel also manages 18 relatively smaller investments, with significant reductions like the 77% cut in Amazon's stake, indicating a focus on optimizing the portfolio and potentially paving the way for future trading opportunities.
See More
Warren Buffett Retires, Greg Abel Takes Over as CEO of Berkshire Hathaway
- Leadership Transition: Warren Buffett retired as CEO on December 31, 2025, with Greg Abel taking over the management of a $320 billion investment portfolio, marking a new era for Berkshire Hathaway, although Buffett remains as chairman of the board.
- Investment Philosophy Continuity: Abel shares a similar investment philosophy with Buffett, emphasizing value investing and sustainable competitive advantages, particularly by allocating a significant portion of the company's capital to their best ideas.
- Core Holdings Concentration: The ten core positions account for nearly 79% of Berkshire's invested assets, all of which pay dividends and engage in share repurchases, demonstrating strong capital return capabilities, with Abel's management style reflected in these choices.
- Smaller Investment Dynamics: Abel oversees 18 smaller holdings ranging from $5 million to approximately $692 million, many of which are being reduced or removed from the portfolio, indicating a dynamic adjustment strategy in response to market conditions.
See More
Jefferies Financial Group Shares Rise 3.3% Amid Middle East Ceasefire
- Stock Price Surge: Jefferies Financial Group's shares rose 3.3% to $48.10 following the ceasefire in the Middle East, reflecting market optimism about the rebound in global equity prices and asset valuations, which directly boosts the company's assets under management and associated fee revenue.
- Return to Risk Assets: The de-escalation in the Middle East encourages retail and institutional investors to rotate back into riskier assets, which is expected to drive revenue growth in investment banking and brokerage divisions, particularly in corporate M&A and advisory activities, creating a potential 'deal-making spring'.
- Market Volatility: Jefferies' stock has experienced 16 moves greater than 5% over the past year; while today's increase is seen as significant, it indicates that the market's fundamental perception of the business remains unchanged, reflecting cautious optimism among investors regarding future prospects.
- Long-Term Investment Returns: Despite a 23.8% decline in Jefferies' stock price year-to-date, investors who purchased $1,000 worth of shares five years ago would now see their investment grow to $1,479, indicating the company's long-term attractiveness, especially in a stable economic environment.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
Jefferies Financial Group Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Jefferies Financial Group and its executives engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Bankruptcy Fallout: Jefferies faces approximately $715 million in debt risk due to its ties with the bankrupt auto parts manufacturer First Brands, resulting in a 7.88% drop in its stock price on October 8, 2025.
- Regulatory Scrutiny: The U.S. Securities and Exchange Commission is investigating whether Jefferies provided sufficient information to investors in its Point Bonita fund, raising further concerns about its transparency in the market.
- Increased Litigation Risk: Western Alliance Bancorp is suing Jefferies, alleging that it failed to fulfill commitments on a large commercial loan, causing its stock price to plummet by 13.53% on March 6, 2026.
See More
